News

October 27, 2017

LiPlaCis Shows Promise in Phase 2 Part of Trial Dealing with Hard to Treat Breast Cancer

News

Three of five patients with breast cancer that had spread to other organs responded to Oncology Ventures’ LiPlaCis or had their disease become stable with it, according to early results of the ... Read more

October 25, 2017

AstraZeneca and Merck Seeking Lynparza Approval in Japan for Certain Breast Cancer Patients

News

AstraZeneca and Merck submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) seeking the approval of Lynparza (olaparib) tablets for the treatment of patients with unresectable or ... Read more

October 23, 2017

Standard-of-Care Control Groups in Breast Cancer Trials Often Not Standard, Study Says

News

Many breast cancer clinical trials that are described as comparing a new treatment with a standard-of-care therapy do not actually make such a comparison, University of Sydney researchers argue. That’s because ... Read more

October 20, 2017October 20, 2017

FDA to Review Lynparza Extension for Certain Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) will review AstraZeneca and Merck‘s application seeking the extension of Lynparza (olaparib) tablets for the treatment of HER-negative metastatic breast cancer patients whose ... Read more

October 18, 2017

Mundipharma EDO Begins Phase 1/2 Trial of Tinostamustine in Triple Negative Breast Cancer, Other Solid Tumors

News

Mundipharma EDO GmbH has initiated a Phase 1/2 clinical trial of tinostamustine (EDO-S101) in patients with advanced triple negative breast cancer (TNBC), ovarian cancer (OC), and other solid tumors. The study ... Read more

October 16, 2017

Breast Cancer Death Rates Drop, but Racial Disparities Remain, American Cancer Society Reports

News

Advances in medicine have significantly lowered death rates in women with breast cancer, but black women are still more likely to die of the disease than white women, according to ... Read more

October 13, 2017

First Breast Cancer Patient in Japanese Trial Receives Entinostat

News

The first patient has been dosed in a pivotal Phase 2 clinical trial in Japan evaluating entinostat as a therapy for hard-to-treat breast cancers. Syndax Pharmaceuticals, which developed the therapy, said the trial (NCT03291886) ... Read more

October 11, 2017

Researchers Develop New Strategy to Target Breast Cancer Metastasis in Bones

News

A new method using small particles loaded with chemotherapy drugs is a viable approach to target breast cancer cells that have spread to the bones, according to a report that ... Read more

October 9, 2017

Synergys Awarded NCI Grant to Develop SYN001 for Triple-negative Breast Cancer

News

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded Synergys Biotherapeutics a grant to support the development of its antibody fusion molecule SYN001 for the treatment of triple negative breast cancer ... Read more

October 6, 2017October 6, 2017

The Angelina Jolie Effect Was Real, Hard Data in US and Australia Confirms

News

Healthcare professionals have speculated for some time that Angelina Jolie’s decision to have a mastectomy in 2013 to reduce her risk of developing breast cancer prompted a lot of other women ... Read more